(Q38160256)

30 August 2017

title

Trabectedin mechanism of action: what's new? (English)

1 reference

30 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Maurizio D'Incalci

series ordinal

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

12 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

5-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

A review of trabectedin (ET-743): a unique mechanism of action.

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Targeting of the innate immunity/inflammation as complementary anti-tumor therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Modelling and simulation: a computational perspective in anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.207

21 January 2018

Identifiers

DOI

10.2217/FON.13.207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24195524%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference